Xeris Biopharma (NASDAQ:XERS) Director Dawn Halkuff Sells 20,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Dawn Halkuff sold 20,000 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $121,800.00. Following the transaction, the director owned 95,000 shares of the company’s stock, valued at $578,550. The trade was a 17.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Stock Performance

Shares of XERS opened at $6.18 on Friday. Xeris Biopharma Holdings, Inc. has a 12 month low of $4.30 and a 12 month high of $10.08. The firm has a fifty day simple moving average of $6.10 and a 200 day simple moving average of $6.59. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of 103.00 and a beta of 0.78. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The business had revenue of $83.13 million during the quarter, compared to analysts’ expectations of $79.83 million. Research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Institutional Trading of Xeris Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its position in Xeris Biopharma by 21.8% during the first quarter. Bank of America Corp DE now owns 874,397 shares of the company’s stock worth $5,072,000 after acquiring an additional 156,483 shares in the last quarter. Janus Henderson Group PLC raised its position in Xeris Biopharma by 322.8% during the first quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock worth $1,713,000 after acquiring an additional 225,602 shares in the last quarter. California State Teachers Retirement System raised its position in Xeris Biopharma by 19.3% during the first quarter. California State Teachers Retirement System now owns 180,339 shares of the company’s stock worth $1,046,000 after acquiring an additional 29,168 shares in the last quarter. Royal Bank of Canada raised its position in Xeris Biopharma by 12.9% during the first quarter. Royal Bank of Canada now owns 43,610 shares of the company’s stock worth $253,000 after acquiring an additional 4,974 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in Xeris Biopharma by 59.0% during the first quarter. The Manufacturers Life Insurance Company now owns 72,804 shares of the company’s stock worth $422,000 after acquiring an additional 27,003 shares in the last quarter. 42.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on XERS. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a report on Monday, March 2nd. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.